RecruitingNCT06887907

Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

Sponsor

University Hospital, Toulouse

Enrollment

40 participants

Start Date

Mar 13, 2025

Study Type

OBSERVATIONAL

Conditions

Sickle Cell Disease (SCD)

Summary

Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Sickle cell disease SS or S-béta° thalassemia
Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome
Age \> 18 years old

Exclusion Criteria4

Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome)
Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23
Anti-platelets agents
Red blood cell exchange or transfusion \< 3 months

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.